{"url_path":"/sec/sybx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1527599/0001193125-26-224171-index.html","accession_number":"0001193125-26-224171","cik":"0001527599","ticker":"SYBX","issuer_name":"SYNLOGIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527599/0001193125-26-224171-index.html","primary_entity_key":"0001527599","primary_entity_name":"SYNLOGIC, INC."},"word_count":883,"has_tables":true,"body_markdown":"10-Q\n\nfalseQ10001527599--12-310001527599us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001527599sybx:OptionsExercisableToPurchaseCommonStockMember2026-03-310001527599us-gaap:CommonStockMember2025-03-310001527599sybx:GinkgoBioworksIncMember2019-06-012019-06-300001527599sybx:GinkgoBioworksIncMember2019-06-300001527599us-gaap:CommonStockMember2024-12-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599sybx:TwoThousandSeventeenAndTwoThousandTwentyFiveEquityIncentiveAwardPlanMember2026-03-310001527599sybx:PreFundedWarrantsMember2026-03-310001527599us-gaap:WarrantMember2026-01-012026-03-310001527599us-gaap:CommonStockMembersybx:UnderwrittenPublicOfferingMember2023-10-032023-10-030001527599us-gaap:RetainedEarningsMember2026-03-310001527599us-gaap:FairValueMeasurementsRecurringMember2025-12-3100015275992026-03-310001527599sybx:UnderwrittenPublicOfferingMembersybx:CommonStockAndWarrantsMembersybx:October2023FinancingMember2023-10-030001527599us-gaap:TreasuryStockCommonMember2025-12-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599us-gaap:RestructuringChargesMember2026-01-012026-03-310001527599us-gaap:RetainedEarningsMember2025-12-310001527599us-gaap:AdditionalPaidInCapitalMember2025-12-310001527599us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001527599us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001527599sybx:CompensationAndBenefitsMember2026-01-012026-03-310001527599us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001527599us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001527599us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001527599us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001527599sybx:GinkgoBioworksIncMembersybx:PreFundedWarrantsMember2019-06-300001527599us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001527599us-gaap:WarrantMember2025-01-012025-12-310001527599us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-3100015275992025-01-012025-03-3100015275992026-05-0700015275992024-12-310001527599us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599sybx:GinkgoBioworksIncMemberus-gaap:CommonStockMember2019-06-012019-06-300001527599us-gaap:RestrictedStockMember2026-03-310001527599sybx:FederalAndStateDeferredTaxMember2025-01-012025-03-310001527599us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599sybx:FacilityAndAllOtherCostsMember2026-01-012026-03-310001527599sybx:UnderwrittenPublicOfferingMembersybx:CommonStockAndWarrantsMember2023-10-030001527599us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001527599us-gaap:RestrictedStockMember2026-01-012026-03-310001527599us-gaap:EmployeeStockOptionMember2026-03-310001527599us-gaap:TreasuryStockCommonMember2025-03-310001527599us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599sybx:PurchaseWarrantsMember2026-03-310001527599sybx:FederalAndStateDeferredTaxMember2026-01-012026-03-310001527599us-gaap:CommonStockMembersybx:UnderwrittenPublicOfferingMember2023-10-030001527599us-gaap:RestructuringChargesMember2025-01-012025-03-310001527599us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599us-gaap:AdditionalPaidInCapitalMember2024-12-310001527599us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001527599sybx:ConsultingAndProfessionalServicesMember2026-01-012026-03-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599sybx:PreFundedWarrantsMember2019-06-300001527599sybx:UnderwrittenPublicOfferingMembersybx:CommonStockAndWarrantsMember2023-10-032023-10-030001527599sybx:FacilityAndAllOtherCostsMember2025-01-012025-03-310001527599us-gaap:WarrantMember2025-12-310001527599sybx:ClinicalResearchAndExternalCostsMember2026-01-012026-03-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599us-gaap:AdditionalPaidInCapitalMember2025-03-310001527599us-gaap:RetainedEarningsMember2025-03-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599sybx:GinkgoBioworksIncMembersybx:PreFundedWarrantsMembersrt:MaximumMember2019-06-300001527599us-gaap:WarrantMembersybx:October2023FinancingMember2026-03-310001527599sybx:ClinicalResearchAndExternalCostsMember2025-01-012025-03-310001527599us-gaap:CommonStockMember2019-06-012019-06-300001527599us-gaap:RetainedEarningsMember2026-01-012026-03-310001527599us-gaap:WarrantMember2026-03-310001527599us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001527599us-gaap:RetainedEarningsMember2025-01-012025-03-310001527599sybx:GinkgoBioworksIncMembersybx:PreFundedWarrantsMember2026-03-310001527599us-gaap:RetainedEarningsMember2024-12-310001527599sybx:CompensationAndBenefitsMember2025-01-012025-03-3100015275992025-03-310001527599us-gaap:AdditionalPaidInCapitalMember2026-03-310001527599us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001527599us-gaap:RestrictedStockMember2025-01-012025-03-310001527599sybx:PurchaseWarrantsMember2026-01-012026-03-310001527599us-gaap:TreasuryStockCommonMember2026-03-310001527599sybx:ConsultingAndProfessionalServicesMember2025-01-012025-03-3100015275992025-12-310001527599sybx:PurchaseWarrantsMember2025-01-012025-03-310001527599us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001527599us-gaap:TreasuryStockCommonMember2024-12-310001527599us-gaap:CommonStockMember2026-03-310001527599us-gaap:CommonStockMember2025-12-310001527599us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-3100015275992026-01-012026-03-310001527599sybx:October2023FinancingMember2026-01-012026-03-310001527599us-gaap:FairValueMeasurementsRecurringMember2026-03-310001527599sybx:UnderwrittenPublicOfferingMembersybx:CommonStockAndWarrantsMembersybx:October2023FinancingMember2023-10-032023-10-030001527599sybx:LongTermIncentivePlan2025Member2026-01-012026-01-01xbrli:pureiso4217:USDxbrli:sharesxbrli:sharessybx:Segmentiso4217:USD\n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\nFORM 10-Q\n\n \n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO\n\n \n\nCommission File Number 001-37566\n\n \n\nSYNLOGIC, INC.\n\n(Exact name of Registrant as specified in its Charter)\n\n \n\nDelaware\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n26-1824804\n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n \n\n \n\nPO Box 30\n\nWinchester, MA\n\n(Address of principal executive offices)\n\n \n\n01890\n\n(Zip Code)\n\n(617) 659-2802\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nNone\n\n \n\n \n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of \"large accelerated filer,\" \"accelerated filer,\" \"smaller reporting company,\" and \"emerging growth company\" in Rule 12b–2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\n \n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\n \n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\nEmerging growth company\n\n☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐\n\n \n\nAs of May 7, 2026, there were 11,696,641 shares of the registrant’s common stock, par value $0.001 per share, outstanding.\n\n \n\n \n\n \n\nFORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:\n\n \n\n•\nour evaluation of strategic alternatives with a goal to enhance stockholder value, including the possibility of a merger or a sale of the Company;\n\n•\nthe price for shares of our common stock given that they are currently quoted on the OTC Marketplace and may experience limited trading;\n\n•\nthe terms and timing of any additional collaborative, licensing or other arrangements that we may establish;\n\n•\nthe acquisition of businesses, products and technologies;\n\n•\nour need to implement additional infrastructure and internal systems; and\n\n•\nother risks and uncertainties, including those listed under Part II, Item 1A. “Risk Factors.”\n\n \n\nAny forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in the “Risk Factors” section contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026 and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.\n\nThis Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.\n\n \n\n \n\nSYNLOGIC, INC.\n\nQUARTERLY REPORT ON FORM 10-Q\n\nTABLE OF CONTENTS\n\n \n\n \n\n \n\nPage\n\n \n\n \n\n \n\nPART I - FINANCIAL INFORMATION"}